Currently, there are no biomarkers used before radiation therapy treatment to identify patients who have altered sensitivity to radiation therapy. This treatment is used in over 67% of cancer patients. MiraDx is developing a panel of such biomarkers, using extensive well-validated patient cohorts. In addition, MiraDx is developing a program to confirm a diagnosis of Ataxia Telangiectasia for children.
As shown in numerous independent studies, women with the KRAS-variant are at an increased risk of developing breast and ovarian cancer, non-small cell lung cancer, and multiple primary breast cancer. For studies about the best cancer prevention strategies for women with the KRAS-variant, please visit our sister non-profit, MiraKind.
New data now indicates that changing estrogen levels and estrogen withdrawal can be triggers for cancer in women with the KRAS-variant. Knowing a woman’s KRAS-variant status is an additional piece of information to help direct decisions for estrogen management as well as screening for this population.
The KRAS-variant has been shown to significantly predict sensitivity and resistant to cancer medicines for cancer patients. This information can subgroup patients into responders or non-responders to therapies being used today as standard of care. Currently work is ongoing to develop the best medicines to treat cancer patients with the KRAS-variant.
Despite the dangers of the KRAS-variant mutation, few doctors have heard of it. But one researcher is trying to change that.